Genprex (NASDAQ:GNPX – Get Free Report) posted its earnings results on Friday. The company reported ($5.30) earnings per share (EPS) for the quarter, FiscalAI reports.
Genprex Trading Down 5.9%
GNPX traded down $0.13 during trading hours on Friday, hitting $2.08. 11,437 shares of the company’s stock were exchanged, compared to its average volume of 114,815. The firm has a market cap of $1.71 million, a P/E ratio of -0.02 and a beta of -0.95. Genprex has a 12-month low of $1.71 and a 12-month high of $98.78. The firm has a 50 day moving average of $2.68 and a 200 day moving average of $18.10.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of “Sell”.
About Genprex
Genprex, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s approach is based on delivering therapeutic genes to diseased cells using non-viral delivery systems, including lipid nanoparticles. Genprex’s lead program, REQORSA Immunogene Therapy, is designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. The company has been evaluating REQORSA in combination with established treatments for non-small cell lung cancer, including targeted and immune-based therapies.
Read More
- Five stocks we like better than Genprex
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.
